ENTRADA THERAPEUTICS INC (TRDA)
Sector: Health Care
2026 Annual Meeting Analysis
ENTRADA THERAPEUTICS INC · Meeting: June 10, 2026
Directors FOR
0
Directors AGAINST
2
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Two Class II Directors
Against Analysis
Dr. Kim has served on the board since December 2020, giving him full tenure overlap with Entrada's severe stock underperformance: the company's shares have fallen 17% over three years while the XBI (SPDR S&P Biotech ETF), the benchmark for biotech companies, gained nearly 66% — a gap of over 82 percentage points, far exceeding the 30-point trigger threshold; the 5-year picture (-47.8% for TRDA vs. a positive XBI return) confirms this is sustained underperformance, not a temporary blip, so no 5-year mitigant applies.
Dr. Zeiher joined the board in April 2023, and by the June 2026 annual meeting his tenure will exceed 24 months, so the new-director exemption no longer protects him; Entrada's stock has lost 17% over three years while the XBI (SPDR S&P Biotech ETF) gained 66% — an 82.6-percentage-point gap that far surpasses the 30-point threshold, and the five-year record (-47.8%) shows this is not a recent or temporary shortfall, so no mitigant applies.
For Analysis
Both Class II director nominees are voted AGAINST due to severe, sustained stock underperformance relative to the XBI (SPDR S&P Biotech ETF): Entrada's shares are down 17% over three years while XBI gained 66%, an 82.6-percentage-point gap that triggers the policy threshold for both directors, and the five-year record confirms the underperformance is not transient.
Say on Pay
✓ FORCEO
Dipal Doshi
Total Comp
$3,837,737
Prior Support
N/A
Entrada is an emerging growth company and is not required to hold a Say on Pay vote; accordingly, no such proposal appears on the 2026 ballot and no prior-year support figure is available. This entry is included for completeness but should be treated as not applicable for this meeting. The compensation structure itself — with base salary representing roughly 17% of the CEO's total pay of $3.8 million, and the remainder in performance-linked equity and cash bonuses tied to stated corporate milestones — reflects a variable pay mix that exceeds the 50-60% policy threshold, and the company has adopted a compliant clawback policy; however, because no formal advisory vote is being held, no binding determination applies.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
5 yrs
Audit Fees
$701,624
Non-Audit Fees
$27,922
Ernst & Young has audited Entrada since 2021 (approximately five years), well below the 25-year tenure threshold; non-audit fees of $27,922 are only about 4% of audit fees of $701,624, comfortably below the 50% independence threshold; and EY is a Big 4 firm appropriate for a company of Entrada's size and complexity.
Overall Assessment
The 2026 Entrada Therapeutics annual meeting presents four proposals; the most consequential issue is the severe and sustained underperformance of the company's stock relative to the XBI (SPDR S&P Biotech ETF) — down 17% over three years versus XBI's gain of 66% — which triggers AGAINST votes for both Class II director nominees (Peter S. Kim and Bernhardt Zeiher) under the policy's TSR accountability framework. The auditor ratification is straightforward and warrants a FOR vote, while the two equity plan amendments are technical corrections to evergreen share-pool formulas and fall outside the current policy's coverage scope.